Comparison Between Env-Specific T-Cell Epitopic Responses in HIV-1-Uninfected Adults Immunized with Combination of ALVAC-HIV(vCP205) Plus or Minus rgp160MN/LAI-2 and HIV-1-Infected Adults-Reference-Cited by-同舟云学术

Comparison Between Env-Specific T-Cell Epitopic Responses in HIV-1-Uninfected Adults Immunized with Combination of ALVAC-HIV(vCP205) Plus or Minus rgp160MN/LAI-2 and HIV-1-Infected Adults

Published:2003-01 Issue:1 Volume:32 Page:9-17
ISSN:1525-4135
Container-title:JAIDS Journal of Acquired Immune Deficiency Syndromes
language:en
Short-container-title:JAIDS Journal of Acquired Immune Deficiency Syndromes

Author:

Ratto-Kim Silvia,Loomis-Price Lawrence D.,Aronson Naomi,Grimes Janelle,Hill Cristin,Williams Chevelle,El Habib Raphaelle,Birx Deborah L.,Kim Jerome H.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Pharmacology (medical),Infectious Diseases

Reference28 articles.

1. The Critical Need for CD4 Help in Maintaining Effective Cytotoxic T Lymphocyte Responses

2. CD4+ T cells are required to sustain CD8+ cytotoxic T-cell responses during chronic viral infection

3. The Role of CD4+T Cell Help and CD40 Ligand in the In Vitro Expansion of HIV-1-Specific Memory Cytotoxic CD8+T Cell Responses

4. T-cell help for cytotoxic T lymphocytes is mediated by CD40–CD40L interactions

5. Induction of interleukin-6 during human immunodeficiency virus infection

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Lessons from the RV144 Thai Phase III HIV-1 Vaccine Trial and the Search for Correlates of Protection;Annual Review of Medicine;2015-01-14

2. The Thai Phase III Trial (RV144) Vaccine Regimen Induces T Cell Responses That Preferentially Target Epitopes within the V2 Region of HIV-1 Envelope;The Journal of Immunology;2012-04-23

3. Phase III HIV vaccine trial in Thailand: a step toward a protective vaccine for HIV;Expert Review of Vaccines;2010-09

4. Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand;New England Journal of Medicine;2009-12-03

5. Therapeutic AIDS Vaccines;Current Pharmaceutical Design;2006-06-01